Acitretin NDC 0093-1135

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-1135Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-1135Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-1135-56	00093113556	30 CAPSULE in 1 BOTTLE (0093-1135-56)Marketed from Jul 19, 2013

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acitretin
Generic name (nonproprietary): acitretin
Active ingredients: Acitretin — 10 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091455
Marketing start: Jul 19, 2013
Listing expires: Dec 31, 2026
Other FDA classes: Retinoids (Chemical structure)
Identifiers: Product ID 0093-1135_11579624-a4a1-4db1-bf72-9fbedbce3225SPL ID 11579624-a4a1-4db1-bf72-9fbedbce3225SPL set ID 993a5325-cd10-4450-b5ea-1c0a90510df6RxCUI 199689, 199690, 894859UNII LCH760E9T7UPC 0300931138569, 0300931135568
Pharmacologic class: Retinoid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093113556 followed by a unit qualifier and the quantity

Package 00093-1135-56. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 19, 2022. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Acitretin Capsules are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, Acitretin Capsules should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, Acitretin Capsules should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — Acitretin Capsules can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 091455

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 091455
Product	Strength	Form · route	Labeler	Product NDC
Acitretin	Acitretin 25 mg/1	CapsuleOral	Teva Pharmaceuticals USA, Inc.	0093-1136